MedTrace Logo

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions

NCT00881738 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-03-28

No results posted yet for this study

Summary

To demonstrate the relative bioavailability of Clarithromycin 250 mg tablets under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Clarithromycin 250 mg Tablets (Geneva, USA)

DRUG

Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)

Sponsors & Collaborators

Principal Investigators

  • So Ran Hong, M.D. · Novum Pharmaceutical Research Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
54 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2002-06-30
Completion
2002-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00881738 on ClinicalTrials.gov